Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic

Status Not yet recruiting

Clinical Trial Summary

This study examines the effect of cord blood in the treatment of newborn infants with neonatal encephalopathy in combination with hypothermia,which is the standard treatment for this condition. The hypothesis is that the cord blood + hypothermia combination will produce better neuroprotection than the standard treatment of hypothermia alone.

Clinical Trial Description

The primary aim of this study is to determine the neuroprotective effect of intravenous administration of autologous cord blood in neonates with severe encephalopathy(hypoxic ischemic encephalopathy or cerebral infarction). It is hypothesized that the administration of autologous cord blood will be safe and well tolerated in neonates with severe encephalopathy. If a neonate is born with signs of moderate to severe encephalopathy and cooled for the encephalopathy, the neonate will receive their own cord blood. The cord blood cells are divided into 3 doses and infused at 24,48,and 72 hours after the birth. Infants will be randomised to treatment with autologous cord blood and hypothermia or hypothermia only and followed for safety and neurodevelopmental outcome up to 18 months. All infants in both groups will be treated with hypothermia for 72 hours started within 6 hours of delivery and infants who allocated to hypothermia and xenon will also receive autologous cord blood in 24 hours from birth through a purpose designed delivery system. Additionally, postnatal neuro-developmental outcomes in neonates with encephalopathy after autologous cord blood therapy will be measured; HIE injury to the neonate/infant brain post autologous cord blood therapy by imaging will be characterized; MRI's will be obtained per clinical routine; serum levels of selected cytokine and neurotrophic factors in neonates with HIE before and after autologous cord blood therapy will be compared and immune cell phenotype and function in neonates with HIE before and after autologous cord blood therapy will be compared. ;

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02605018
Study type	Interventional
Source	The People's Hospital of Dehong Autonomous Prefecture
Contact	Zhaoqing Yin, bachelor
Email	zhaoqingyin99@sina.com
Status	Not yet recruiting
Phase	Phase 1/Phase 2
Start date	November 2015
Completion date	December 2018

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02551003` - Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy	Phase 1/Phase 2
Completed	`NCT03281590` - Stroke and Cerebrovascular Diseases Registry
Recruiting	`NCT03605381` - MORbidity PRevalence Estimate In StrokE
Completed	`NCT00684515` - Trial to Assess the Safety of Vorapaxar in Japanese Subjects With Cerebral Infarction (P05005; MK-5348-017)	Phase 2
Not yet recruiting	`NCT04082091` - Screening, Early Referral and Lifestyle Tailored E_prescription for Cardiovascular Prevention
Completed	`NCT01915368` - Determining Optimal Post-Stroke Exercise (DOSE)	N/A
Terminated	`NCT01684462` - The Efficacy and Safety Study of ALbumin Therapy in Acute Ischemic Stroke	Phase 2
Completed	`NCT00386191` - Safety and Efficacy of Clopidogrel for Cerebral Infarction Treatment	Phase 4
Completed	`NCT00004734` - Vitamin Therapy for Prevention of Stroke	Phase 3
Completed	`NCT02684825` - Detection of Silent Atrial Fibrillation aFter Ischemic StrOke	N/A
Completed	`NCT02248233` - Nimodipine for Treating Acute Massive Cerebral Infarction	Phase 4
Completed	`NCT02963545` - TSK (Tryptophan - Serotonin - Kynurenine) Biomarkers Assessment in Stroke	N/A
Completed	`NCT02511249` - Early Determinants of Multidimensional Outcome at School Age After Neonatal Arterial Ischemic Stroke	N/A
Completed	`NCT02101606` - Penumbral Based Novel Thrombolytic Therapy in Acute Ischemic Stroke	Phase 2
Completed	`NCT01500421` - Safty and Feasibility Study of Therapeutic Cooling in Acute Ischemic Stroke (COOLAID Øresund)	Phase 2
Completed	`NCT00829361` - Stroke Telemedicine for Arizona Rural Residents Trial	N/A
Recruiting	`NCT01003470` - Treating Apoplectic Sequela With Acupuncture: a Randomized Controlled Study	Phase 2
Terminated	`NCT00331890` - ICTUS Study: International Citicoline Trial on Acute Stroke	Phase 3
Not yet recruiting	`NCT04696523` - Effect of Xenon on Brain Injury After Aneurysmal Subarachnoid Hemorrhage	Phase 2
Completed	`NCT03741400` - Virtual Reality Glove for Hand and Arm Rehabilitation After Stroke	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Neuroprotective Effect of Autologous Cord Blood Combined With Therapeutic Hypothermia Following Neonatal Encephalopathy

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms